NCT02004704View on ClinicalTrials.gov

A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 4, 2013

Primary Completion Date

September 6, 2023

Study Completion Date

September 6, 2023

Conditions
Sphingomyelin Lipidosis
Interventions
DRUG

GZ402665

"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"

Trial Locations (9)

3000

Investigational Site Number 056001, Leuven

33100

Investigational Site Number 380001, Udine

65239

Investigational Site Number 276002, Hochheim am Main

69677

Investigational Site Number 250002, Bron

10029-6574

Investigational Site Number 840001, New York

90035 003

Investigational Site Number 076001, Porto Alegre

07100

Investigational Site Number 380002, Sassari

WC1N 3JZ

Investigational Site Number 826001, London

M13 9WL

Investigational Site Number 826002, Manchester

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02004704 - A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | Biotech Hunter | Biotech Hunter